180 related articles for article (PubMed ID: 15579019)
1. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
Agulnik M; Siu LL
Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):543-51. PubMed ID: 15579019
[TBL] [Abstract][Full Text] [Related]
2. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.
Surakanti SG; Agulnik M
Semin Oncol; 2008 Jun; 35(3):309-19. PubMed ID: 18544445
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
Milano A; Longo F; Basile M; Iaffaioli RV; Caponigro F
Oral Oncol; 2007 Sep; 43(8):729-34. PubMed ID: 17350323
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
Oral Oncol; 2012 Oct; 48(10):948-957. PubMed ID: 22698431
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for salivary gland cancer.
Suen JY; Johns ME
Laryngoscope; 1982 Mar; 92(3):235-9. PubMed ID: 6279995
[TBL] [Abstract][Full Text] [Related]
9. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
Dodd RL; Slevin NJ
Oral Oncol; 2006 Sep; 42(8):759-69. PubMed ID: 16757203
[TBL] [Abstract][Full Text] [Related]
10. Salivary Gland Cancers: Biology and Systemic Therapy.
Goyal G; Mehdi SA; Ganti AK
Oncology (Williston Park); 2015 Oct; 29(10):773-80. PubMed ID: 26470903
[TBL] [Abstract][Full Text] [Related]
11. [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
Golusiński W; Wegner A; Trzeciak P; Golusiński P; Sówka M; Kopczyński A; Bromboszcz M; Marszałek A
Otolaryngol Pol; 2013; 67(5):245-51. PubMed ID: 24021827
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
13. A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network).
Cerda T; Sun XS; Vignot S; Marcy PY; Baujat B; Baglin AC; Ali AM; Testelin S; Reyt E; Janot F; Thariat J
Crit Rev Oncol Hematol; 2014 Aug; 91(2):142-58. PubMed ID: 24636481
[TBL] [Abstract][Full Text] [Related]
14. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Vattemi E; Graiff C; Sava T; Pedersini R; Caldara A; Mandarà M
Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
[TBL] [Abstract][Full Text] [Related]
16. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
[TBL] [Abstract][Full Text] [Related]
17. Update and perspectives on non-surgical treatment of salivary gland malignancies.
Airoldi M; Cortesina G; Giordano C; Pedani F; Cavalot A; Marcato P; Beatrice F; Bumma C
Acta Otorhinolaryngol Ital; 2003 Oct; 23(5):368-76. PubMed ID: 15108487
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for salivary gland cancer.
Kaplan MJ; Johns ME; Cantrell RW
Otolaryngol Head Neck Surg; 1986 Sep; 95(2):165-70. PubMed ID: 3035459
[TBL] [Abstract][Full Text] [Related]
19. Salivary gland cancers: current treatments, molecular characteristics and new therapies.
Chandana SR; Conley BA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):645-52. PubMed ID: 18402531
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy in the palliative management of advanced salivary gland cancers.
Laurie SA; Licitra L
J Clin Oncol; 2006 Jun; 24(17):2673-8. PubMed ID: 16763282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
